Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie W Lees

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
The American Journal of Gastroenterology|August 16, 2022
The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD)Hassan Azhari, James A King, Stephanie Coward, et al.
Inflammatory Bowel Diseases|August 21, 2023
Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United KingdomSamuel Hsiang Lim, Beatriz Gros, Esha Sharma, et al.
Plos Medicine|December 17, 2008
Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathwaysCharlie W Lees, William J Zacharias, Mark Tremelling, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort studyZhigang Liu, Kaixing Le, Xin Zhou, et al.
Gut|September 9, 2011
NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2Aleixo M Muise, Wei Xu, Cong-Hui Guo, et al.
The Lancet. Gastroenterology & Hepatology|January 28, 2021
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statementJames L Alexander, Gordon W Moran, Daniel R Gaya, et al.
Gut|July 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemicNicholas A Kennedy, Malik Janjua, Neil Chanchlani, et al.
Frontline Gastroenterology|September 3, 2020
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemicNicholas A Kennedy, Richard Hansen, Lisa Younge, et al.
Gastroenterology|October 11, 2019
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's DiseaseAleksejs Sazonovs, Nicholas A Kennedy, Loukas Moutsianas, et al.
Gut|April 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDNicholas A Kennedy, Simeng Lin, James R Goodhand, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
The American Journal of Gastroenterology|August 16, 2022
The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD)Hassan Azhari, James A King, Stephanie Coward, et al.
Inflammatory Bowel Diseases|August 21, 2023
Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United KingdomSamuel Hsiang Lim, Beatriz Gros, Esha Sharma, et al.
Plos Medicine|December 17, 2008
Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathwaysCharlie W Lees, William J Zacharias, Mark Tremelling, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort studyZhigang Liu, Kaixing Le, Xin Zhou, et al.
Gut|September 9, 2011
NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2Aleixo M Muise, Wei Xu, Cong-Hui Guo, et al.
The Lancet. Gastroenterology & Hepatology|January 28, 2021
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statementJames L Alexander, Gordon W Moran, Daniel R Gaya, et al.
Gut|July 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemicNicholas A Kennedy, Malik Janjua, Neil Chanchlani, et al.
Frontline Gastroenterology|September 3, 2020
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemicNicholas A Kennedy, Richard Hansen, Lisa Younge, et al.
Gastroenterology|October 11, 2019
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's DiseaseAleksejs Sazonovs, Nicholas A Kennedy, Loukas Moutsianas, et al.
Gut|April 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDNicholas A Kennedy, Simeng Lin, James R Goodhand, et al.
Pageof 10